This clinical study is investigating a new heart imaging agent, 18F-mFBG, which is used in a type of scan called a PET scan. The goal is to see how well it works for people with Lewy Body Dementia, a condition affecting the brain similar to Parkinson's disease. The study compares heart images from individuals with Lewy Body Dementia to those without it.

Here's what you should know:

• The study includes adults aged 18 and older who meet certain health criteria.
• Participants will undergo heart imaging to test the new agent's effectiveness.
• Exclusions include recent participation in other studies or certain health conditions.

Lewy Bodies are abnormal protein deposits in the brain that affect thinking and movement. 18F-mFBG is a type of radiopharmaceutical, meaning it uses radioactive material to help doctors see inside the body. This study is important because it could improve how doctors diagnose and treat people with these brain conditions.